2- ((2,6- dichlorophenyl)amino)benzeneacetic acid 4-(3H-1,2-dithiol-3-thione-5-yl)phenyl ester

an NSAID; structure in first source

Also Known As:

S-diclofenac

Networked: 7 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Carbocyclic Acids
    - Phenylacetates: 3
      - Diclofenac: 4384
        2-((2,6-dichlorophenyl)amino)benzeneacetic acid 4-(3H-1,2-dithiol-3-thione-5-yl)phenyl ester: 7
- Sulfur Compounds: 278
  - Thiones: 70
    - 2-((2,6-dichlorophenyl)amino)benzeneacetic acid 4-(3H-1,2-dithiol-3-thione-5-yl)phenyl ester: 7
Inorganic Chemicals: 9
- Thiones: 70
  - 2-((2,6-dichlorophenyl)amino)benzeneacetic acid 4-(3H-1,2-dithiol-3-thione-5-yl)phenyl ester: 7

Experts

1.	Sparatore, Anna: 5 articles (01/2011 - 03/2007)
2.	Del Soldato, Piero: 4 articles (05/2010 - 03/2007)
3.	Del Soldato, P: 2 articles (03/2012 - 01/2008)
4.	Sparatore, A: 2 articles (03/2012 - 01/2008)
5.	Moody, Terry W: 2 articles (05/2010 - 03/2009)
6.	Roberts, David D: 2 articles (05/2010 - 03/2009)
7.	Wink, David A: 2 articles (05/2010 - 03/2009)
8.	Moore, Philip Keith: 2 articles (10/2008 - 03/2007)
9.	Frantzias, J: 1 article (03/2012)
10.	Idris, A I: 1 article (03/2012)

Related Diseases

1.	Cardiomyopathies (Cardiomyopathy) 01/01/2011 - "As a result, S-diclofenac significantly attenuated doxorubicin-related cardiac injury and cardiac dysfunction, and improved the survival rate of mice with doxorubicin-induced cardiomyopathy. " 01/01/2011 - "Therefore, we propose that H(2)S released from S-diclofenac in vivo contributes to the protective effect in doxorubicin-induced cardiomyopathy. " 01/01/2011 - "S-diclofenac protects against doxorubicin-induced cardiomyopathy in mice via ameliorating cardiac gap junction remodeling." 01/01/2011 - "In the present study, we investigated the cardioprotective effect of S-diclofenac (2-[(2,6-dichlorophenyl)amino] benzeneacetic acid 4-(3H-1,2,dithiol-3-thione-5-yl)phenyl ester), a novel H(2)S-releasing derivative of diclofenac, in a murine model of doxorubicin-induced cardiomyopathy. "
2.	Reperfusion Injury 01/01/2008 - "This study investigated the pharmacological activity of a new H(2)S-releasing derivative of diclofenac, S-diclofenac (2-[(2,6-dichlorophenyl)amino]benzeneacetic acid 4-(3H-1,2-dithiole-3-thione-5-yl)-phenyl ester) in the isolated rabbit heart submitted to low-flow ischaemia-reperfusion damage. " 01/01/2008 - "Perfusion with the nitric oxide (NO) synthase inhibitor N(G)-monomethyl-L-arginine worsened the myocardial ischaemia-reperfusion damage, but this was dose-dependently prevented by S-diclofenac and NaHS, suggesting that the released H(2)S may have overcome NO deficiency. "
3.	Vascular System Injuries 10/10/2008 - "S-diclofenac inhibits smooth muscle cell growth and may play a role in the lesion formation at sites of the vascular injury. "
4.	Osteolysis 03/01/2012 - "S-diclofenac derivatives inhibit osteoclast formation and activity, suppress breast cancer cell support for osteoclastogenesis and prevent osteolysis. "
5.	Inflammation (Inflammations) 03/01/2007 - "S-diclofenac administration inhibited lipopolysaccharide-induced inflammation (as evidenced by reduced lung and liver myeloperoxidase activity) and caused significantly less gastric toxicity than diclofenac. "

Related Drugs and Biologics

1.	Doxorubicin (Adriamycin)
2.	Diclofenac (SR 38)
3.	Thiones
4.	Esters
5.	Acids
6.	dithiol
7.	S-sulindac
8.	Nitric Oxide Synthase (NO Synthase)
9.	Valproic Acid (Depakote)
10.	Epoprostenol (Prostacyclin)